Kiniksa Pharmaceuticals International, plc (KNSA) stock
KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 14/30469% above fair value
$95.11+0.88 (+0.93%)
Close on Nov 17, 2026Market cap $14.95BP/E 73.2Yield –
Kiniksa Pharmaceuticals International price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Kiniksa Pharmaceuticals International's price to sales ratio was 9.3× on Nov 11, 2026, against 5.4× a year earlier. Over the last 5 years it ranged from 3.4× to 18.2×, with a median of 5.3×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 9.3× | +4.0 |
| 2025 | Dec 31, 2025 | 5.3× | +1.5 |
| 2024 | Dec 31, 2024 | 3.7× | −1.2 |
| 2023 | Dec 29, 2023 | 5.0× | −0.9 |
| 2022 | Dec 30, 2022 | 5.9× | – |
See a number that looks wrong?